TY  - JOUR
AU  - Martín-Garcia, Ana
AU  - López-Fernández, Teresa
AU  - Mitroi, Cristina
AU  - Chaparro-Muñoz, Marinela
AU  - Moliner, Pedro
AU  - Martin-Garcia, Agustin C
AU  - Martinez-Monzonis, Amparo
AU  - Castro, Antonio
AU  - Lopez-Sendon, Jose L
AU  - Sanchez, Pedro L
PY  - 2020
DO  - 10.1002/ehf2.12627
UR  - http://hdl.handle.net/10668/15049
T2  - ESC heart failure
AB  - Current guidelines recommend sacubitril/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction (CTRCD)....
LA  - en
KW  - Cancer
KW  - Cardio-oncology
KW  - Cardiotoxicity
KW  - Heart failure
KW  - Sacubitril-valsartan
KW  - Aged
KW  - Aminobutyrates
KW  - Biphenyl Compounds
KW  - Drug Combinations
KW  - Female
KW  - Heart Failure
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Retrospective Studies
KW  - Stroke Volume
KW  - Valsartan
KW  - Ventricular Function, Left
TI  - Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
TY  - research article
VL  - 7
ER  -